What it is
Gramicidin is an antibiotic made of a short peptide chain, produced by a soil bacterium. In 1939 René Dubos, at the Hospital of the Rockefeller Institute, reported isolating a Gram-positive, spore-forming soil bacillus whose cultures released a soluble agent that killed every Gram-positive species tested and was ineffective against all the Gram-negative bacilli tested (Dubos 1939, J Exp Med, PMID 19870884). That agent became tyrothricin, and its two components gramicidin and tyrocidine — the names Dubos himself used in a 1959 retrospective, Tyrothricin, gramicidin, and tyrocidine — twenty years later (PMID 13818331).
The natural product is a mixture — gramicidin A, B and C — often sold as gramicidin D. Gramicidin A is the main component:
| Property | Gramicidin A | Gramicidin S | Source |
|---|---|---|---|
| Shape | Linear chain | Closed ring | PubChem |
| Length | 15 amino acids | 10 amino acids | PubChem |
| Formula | C99H140N20O17 | C60H92N12O10 | PubChem CIDs 16132269, 73357 |
| Molecular weight | 1,882.3 | 1,141.4 | PubChem |
| Ends | Formyl group at the start, ethanolamine at the end | None — it is a ring | PubChem name |
The unusual feature is the alternating handedness. Amino acids in most proteins are all the left-handed (L) form. In gramicidin A, the PubChem chemical name assigns the residues alternately to L and D forms along the chain — formyl-Val, Gly, Ala, then D-Leu, L-Ala, D-Val and so on to four tryptophans near the end. A chain built this way can coil into a helix with a hollow core, which is what makes a channel possible.
Gramicidin S is a different molecule with a confusingly similar name: a 10-residue ring with its own formula, now studied mainly as a template for new antibiotic analogues (reviews of 2019 and 2025, PMIDs 30938996, 40683145). It belongs in a separate record, and nothing on this page about gramicidin A should be read across to it.
How it works
Two gramicidin A molecules join across a cell membrane to form the working channel — solid-state NMR work on the "gramicidin A channel dimer" in hydrated lipid membranes is one line of that evidence (PMID 10805133). A 2007 review describes the result as a prototypical ion channel specific for monovalent cations — sodium, potassium, hydrogen ions — and notes it has been "extensively used" to study how membrane channels are organised and how they work (Kelkar and Chattopadhyay, Biochim Biophys Acta, PMID 17572379). The review's own point is that crystal structures of large natural channels have since challenged gramicidin's role as the model, while its tryptophans remain a reference for how channels anchor in a membrane.
Its medical use is topical only, on the label described below. Tonight's sources do not quantify toxicity to human cells, so this entry gives no figure for it.
In medicine today
The one current US product found in Drugs@FDA is a prescription eye solution combining three antibiotics (ANDA 064047, Bausch & Lomb; label effective 2026-02-04). The label lists, per mL:
| Ingredient | Amount per mL |
|---|---|
| Neomycin sulfate | equivalent to 1.75 mg neomycin base |
| Polymyxin B sulfate | 10,000 polymyxin B units |
| Gramicidin | 0.025 mg |
It is indicated for superficial infections of the external eye and its adnexa — conjunctivitis, keratitis, blepharitis and related infections caused by susceptible bacteria. Gramicidin's partners are covered in the library's polymyxin B entry; the bacitracin entry covers another peptide antibiotic used on the skin. Because the product combines three drugs, no trial on its label isolates what gramicidin alone contributes.
ClinicalTrials.gov lists 10 studies naming gramicidin (2026-11-17). Two concern eye drops after procedures; three recent ones, phase 1 and phase 2, test Grammidin, a metered-dose throat spray with and without an anaesthetic, the largest planned at 300 participants. Those are records of registered studies, not results.
Where it stands
Gramicidin is an old, narrow, topical antibiotic with one current US use as part of a combination eye drop, and a long second life as a laboratory tool. It is not a research peptide sold for any other purpose. The library's nisin entry covers a peptide antibiotic made by a different bacterium and used in food; peptides for immunity places the antimicrobial peptides side by side.
Sources opened 2026-11-17: Dubos 1939, J Exp Med (PMID 19870884, part I of three); Dubos 1959 retrospective (PMID 13818331, record); gramicidin A channel dimer NMR study (PMID 10805133, record); gramicidin S reviews (PMIDs 30938996, 40683145, records); Kelkar and Chattopadhyay 2007 (PMID 17572379); PubChem CIDs 16132269 and 73357; neomycin, polymyxin B and gramicidin ophthalmic solution label (openFDA, effective 2026-02-04); Drugs@FDA ANDA 064047; PubMed E-utilities and ClinicalTrials.gov API v2 counts.
